{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:29:01Z","timestamp":1793806141153,"version":"4.6.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific research project of Shanxi Traditional Chinese Medicine Administration","award":["2024ZYY2B026"],"award-info":[{"award-number":["2024ZYY2B026"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,25]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This bibliometric study aimed to map the global research landscape of immunotherapy for biliary tract cancers (BTC) from 2014 to 2023, identifying key contributors and emerging trends.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed 481 English-language articles retrieved from the Web of Science Core Collection (2014\u20132023) using CiteSpace. Parameters included coauthorship, co-citation, keyword co-occurrence, and burst detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Annual publications surged by 80% in 2021 versus 2020. China dominated output (50% of publications), with Fudan University as the top institution. Fan Jia was the most prolific author (7 papers). High-frequency keywords included gemcitabine (first-line chemotherapy), tumor microenvironment, and T cells. Burst keywords indicated emerging foci: tumor-infiltrating lymphocytes and growth factor receptor (e.g., HER2\/ERBB2). The most co-cited study (Piha-Paul et al, 2020; 106 citations) reported pembrolizumab efficacy in BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Research accelerated post-2020, driven by clinical trials. China, Fudan University, and Fan Jia are central to BTC immunotherapy research. Future priorities include targeting HER2 and the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046834","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:01:19Z","timestamp":1790359279000},"page":"e46834","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Research hotspots and trends in biliary tract cancers immunotherapy are revealed by a bibliometric study spanning the years 2014 to 2024"],"prefix":"10.1097","volume":"105","author":[{"given":"Yanyan","family":"Miu","sequence":"first","affiliation":[{"name":"Department of Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5992-2662","authenticated-orcid":false,"given":"Zhongbiao","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261104","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer.","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"R2-20261104","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3390\/cancers13071569","article-title":"Immunotherapy in advanced biliary tract cancers.","volume":"13","author":"Boileve","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R3-20261104","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012.","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"key":"R4-20261104","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/annonc\/mdn533","article-title":"Epidemiology of biliary tract cancers: an update.","volume":"20","author":"Randi","year":"2009","journal-title":"Ann Oncol"},{"key":"R5-20261104","doi-asserted-by":"crossref","first-page":"448","DOI":"10.37349\/etat.2021.00056","article-title":"A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?","volume":"2","author":"Aimar","year":"2021","journal-title":"Explor Target Antitumor Ther"},{"key":"R6-20261104","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis.","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"R7-20261104","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2019.04.003","article-title":"Immunotherapy of colorectal cancer: challenges for therapeutic efficacy.","volume":"76","author":"Ciardiello","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"R8-20261104","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fimmu.2017.00829","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models.","volume":"8","author":"Decker","year":"2017","journal-title":"Front Immunol"},{"key":"R9-20261104","doi-asserted-by":"crossref","first-page":"e32081","DOI":"10.1097\/MD.0000000000032081","article-title":"Scientometric analysis of kidney disease and gut microbiota from 2001 to 2020 based on Web of Science.","volume":"101","author":"Zhang","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R10-20261104","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpedi.160.10.1005","article-title":"Cardiorespiratory fitness levels among US youth 12 to 19 years of age: findings from the 1999-2002 National Health and Nutrition Examination Survey.","volume":"160","author":"Pate","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R11-20261104","doi-asserted-by":"crossref","first-page":"e37782","DOI":"10.1097\/MD.0000000000037782","article-title":"Research hotspots and trends in the relationship between sport and nutrition: a bibliometric analysis from 2013 to 2023.","volume":"103","author":"Tao","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R12-20261104","doi-asserted-by":"crossref","first-page":"e36460","DOI":"10.1097\/MD.0000000000036460","article-title":"Research hotspots and trends in the relationship between genetics and major depressive disorder: a scientometric analysis from 2003 to 2023.","volume":"102","author":"Zhao","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R13-20261104","first-page":"401","article-title":"CiteSpace I: detecting and visualizing emerging trends and transient patterns in scientific literature.","volume":"28","author":"Chen","year":"2009","journal-title":"J China Soc Sci Tech Inf"},{"key":"R14-20261104","doi-asserted-by":"crossref","first-page":"e38846","DOI":"10.1097\/MD.0000000000038846","article-title":"A bibliometric analysis from 2013 to 2023 reveals research hotspots and trends in the connection between sport and regenerative medicine.","volume":"103","author":"Xiongce","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R15-20261104","doi-asserted-by":"crossref","first-page":"e38435","DOI":"10.1097\/MD.0000000000038435","article-title":"A bibliometric analysis from 2013 to 2024 reveals research hotspots and trends in the connection between atrial fibrillation and cryoballoon: an observational study.","volume":"103","author":"Lu","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R16-20261104","doi-asserted-by":"crossref","first-page":"e34973","DOI":"10.1097\/MD.0000000000034973","article-title":"Research hotspots and trends on post-cesarean section analgesia: a scientometric analysis from 2001 to 2021.","volume":"102","author":"Zhao","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R17-20261104","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.","volume":"30","author":"Kim","year":"2019","journal-title":"Ann Oncol"},{"key":"R18-20261104","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","article-title":"Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial.","volume":"162","author":"Cousin","year":"2022","journal-title":"Eur J Cancer"},{"key":"R19-20261104","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R20-20261104","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R21-20261104","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management.","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R22-20261104","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer.","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"R23-20261104","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies.","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int J Cancer"},{"key":"R24-20261104","first-page":"3437","article-title":"Cancers of the pancreas and biliary tract: epidemiological considerations.","volume":"35","author":"Fraumeni","year":"1975","journal-title":"Cancer Res"},{"key":"R25-20261104","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","article-title":"Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.","volume":"19","author":"Gebbia","year":"2001","journal-title":"J Clin Oncol"},{"key":"R26-20261104","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/annonc\/mdh096","article-title":"Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.","volume":"15","author":"Kornek","year":"2004","journal-title":"Ann Oncol"},{"key":"R27-20261104","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1200\/JCO.1997.15.1.297","article-title":"Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.","volume":"15","author":"Crino","year":"1997","journal-title":"J Clin Oncol"},{"key":"R28-20261104","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-20261104","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"R30-20261104","doi-asserted-by":"crossref","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer.","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"R31-20261104","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R32-20261104","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment.","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R33-20261104","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","article-title":"Immunosuppressive networks in the tumour environment and their therapeutic relevance.","volume":"5","author":"Zou","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"R34-20261104","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing.","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"R35-20261104","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.21037\/jgo.2019.08.08","article-title":"Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.","volume":"10","author":"Mody","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"R36-20261104","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management.","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:00:30Z","timestamp":1793804430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000046834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":36,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046834","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2025-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}